Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 28, 2024
Product Development

Clinical Report: U.K. details plans to improve clinical trial infrastructure

Plus: Neurocrine’s schizophrenia therapy, Medicxi-backed Vaderis’ treatment for rare vascular disorder both look to advance; plus a miss for Leo’s Timber
BioCentury | Mar 9, 2024
Discovery & Translation

Science spotlight: Elixirgen’s full-length dystrophin gene therapy, Insilico’s TNIK inhibitor and more

BioCentury’s roundup of translational innovations
BioCentury | Feb 20, 2024
Distillery Therapeutics

Inhibiting epithelial SIRT6 for asthma

BioCentury | Oct 1, 2021
Distillery Therapeutics

Agonizing RARG to reduce doxorubicin-induced cardiotoxicity

BioCentury | Dec 20, 2019
Emerging Company Profile

Centaurus: inhibiting ceramide synthesis for cardiometabolic disease

Centaurus is developing DEGS1 inhibitors to block lipotoxicity in cardiometabolic diseases
BioCentury | Mar 26, 2019
Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

BioCentury | Mar 25, 2019
Distillery Therapeutics

Inhibiting RAR for retinitis pigmentosa

Items per page:
1 - 10 of 152
Help Center
Username
Request a Demo
Request Training
Ask a Question